326 related articles for article (PubMed ID: 21461027)
1. [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
de Alarcón Jiménez RM; Roca Meroño S; Alvarez Fernández GM; García Hernández MA; Navarro Parreño MJ; Jimeno Griñó C; Zarco Pedrinaci E; Molina Núñez M
Nefrologia; 2011; 31(2):238-40. PubMed ID: 21461027
[No Abstract] [Full Text] [Related]
2. DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
Lemaire O; Attal M; Bourin P; Laroche M
Eur J Haematol; 2010 Mar; 84(3):276-7. PubMed ID: 19891699
[No Abstract] [Full Text] [Related]
3. Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Dasanu CA; Reale MA; Bauer F
Leuk Res; 2010 Jul; 34(7):e178-80. PubMed ID: 20079532
[No Abstract] [Full Text] [Related]
4. Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation.
Witzens-Harig M; Waldherr R; Beimler J; Zeier M; Hansmann J; Ho AD; Goldschmidt H; Moehler T
Ann Hematol; 2007 Dec; 86(12):927-30. PubMed ID: 17605010
[No Abstract] [Full Text] [Related]
5. [Hematopoietic stem cell transplantation for multiple myeloma].
Kanda Y
Rinsho Ketsueki; 2009 Oct; 50(10):1420-6. PubMed ID: 19915350
[No Abstract] [Full Text] [Related]
6. [Improved prognosis in light chain nephropathy due to multiple myeloma].
Juul JS; Larsen T; Marcussen N; Pedersen EB
Ugeskr Laeger; 2012 Apr; 174(17):1159-60. PubMed ID: 22533933
[TBL] [Abstract][Full Text] [Related]
7. Achieving an early myeloma response in patients with kidney impairment.
Stringer S; Cook M; Cockwell P
Adv Chronic Kidney Dis; 2012 Sep; 19(5):303-11. PubMed ID: 22920641
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD; Lechowicz MJ; Khoury HJ; Flowers CR; Waller EK
Clin Cancer Res; 2010 Oct; 16(20):5079-86. PubMed ID: 20739431
[TBL] [Abstract][Full Text] [Related]
9. Lambda light chain myeloma with oliguric cast nephropathy and remission with bortezomib, doxorubicin and dexamethasone.
Hada R; Poudyal B; Sharma A; Khatri R
JNMA J Nepal Med Assoc; 2012; 52(188):192-5. PubMed ID: 23591252
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
11. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
12. Myeloma presenting during pregnancy.
Smith D; Stevens J; Quinn J; Cavenagh J; Ingram W; Yong K
Hematol Oncol; 2014 Mar; 32(1):52-5. PubMed ID: 23996410
[No Abstract] [Full Text] [Related]
13. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
[TBL] [Abstract][Full Text] [Related]
14. Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma.
Pogłód R; Kraj M; Kruk B; Hagedorna-Tronina R; Łetowska M; Warzocha K
Leuk Lymphoma; 2010 Dec; 51(12):2291-4. PubMed ID: 20929320
[No Abstract] [Full Text] [Related]
15. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
16. Oligoclonal reconstitution masquerading as myeloma relapse.
Chim CS; Chan EY
Ann Hematol; 2013 Jun; 92(6):847-8. PubMed ID: 23150202
[No Abstract] [Full Text] [Related]
17. Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
Chim CS; Choi PT; Lee WK
Ann Hematol; 2013 Jun; 92(6):855-7. PubMed ID: 23183880
[No Abstract] [Full Text] [Related]
18. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
19. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.
Silvennoinen R; Kairisto V; Pelliniemi TT; Putkonen M; Anttila P; Säily M; Sikiö A; Opas J; Penttilä K; Kuittinen T; Honkanen T; Lundán T; Juvonen V; Luukkaala T; Remes K
Br J Haematol; 2013 Feb; 160(4):561-4. PubMed ID: 23206270
[No Abstract] [Full Text] [Related]
20. [New treatment strategies for multiple myeloma].
Ozaki S
Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
[No Abstract] [Full Text] [Related]
[Next] [New Search]